

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 December 2021 (16.12.2021)



(10) International Publication Number
WO 2021/252491 A1

(51) International Patent Classification:

C07D 403/14 (2006.01) C07F 9/572 (2006.01)
C07D 405/14 (2006.01) A61K 31/4025 (2006.01)
C07D 409/14 (2006.01) A61K 31/4439 (2006.01)
C07D 413/14 (2006.01) A61P 31/14 (2006.01)
C07D 417/14 (2006.01) A61P 31/16 (2006.01)

(21) International Application Number:

PCT/US2021/036403

(22) International Filing Date:

08 June 2021 (08.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/037,200	10 June 2020 (10.06.2020)	US
63/055,679	23 July 2020 (23.07.2020)	US
63/085,871	30 September 2020 (30.09.2020)	US
63/086,787	02 October 2020 (02.10.2020)	US
63/125,562	15 December 2020 (15.12.2020)	US
63/155,113	01 March 2021 (01.03.2021)	US

(71) Applicants: **ALIGOS THERAPEUTICS, INC.** [US/US];
1 Corporate Drive, 2nd Floor, South San Francisco, California 94080 (US). **KATHOLIEKE UNIVERSITEIT LEUVEN** [BE/BE]; KU Leuven Research & Development, Waaistraat 6, bus 5105, B-3000 Leuven (BE).

(72) Inventors: **VANDYCK, Koen**; c/o Aligos Therapeutics, Inc., 1 Corporate Drive, 2nd Floor, South San Francisco, California 94080 (US). **RABOISSON, Pierre, Jean-Marie, Bernard**; c/o Aligos Therapeutics, Inc., 1 Corporate Drive, 2nd Floor, South San Francisco, California 94080 (US). **BEIGELMAN, Leonid**; c/o Aligos Therapeutics, Inc., 1 Corporate Drive, 2nd Floor, South San Francisco, California 94080 (US).

co, California 94080 (US). **SEREBRYANY, Vladimir**; c/o Aligos Therapeutics, Inc., 1 Corporate Drive, 2nd Floor, South San Francisco, California 94080 (US). **STOYCHEVA, Antitsa, Dimitrova**; c/o Aligos Therapeutics, Inc., 1 Corporate Drive, 2nd Floor, South San Francisco, California 94080 (US). **BARDIOT, Dorothée, Alice, Marie-Eve**; c/o Katholieke Universiteit Leuven, KU Leuven Research & Development, Waaistraat 6, bus 5105, B-3000 Leuven (BE). **BOLAND, Sandro**; c/o Katholieke Universiteit Leuven, KU Leuven Research & Development, Waaistraat 6, bus 5105, B-3000 Leuven (BE). **MARCHAND, Arnaud, Didier, Marie**; c/o Katholieke Universiteit Leuven, KU Leuven Research & Development, Waaistraat 6, bus 5105, B-3000 Leuven (BE).


(74) Agent: **MILLER, Kimberly, J.**; Knobbe Martens Olson & Bear LLP, 2040 Main Street, Fourteenth Floor, Irvine, California 92614 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS

(57) Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating coronavirus, Picornavirus and Norovirus infections with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.



(I)

WO 2021/252491 A1

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*